FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending September 16, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 
GlaxoSmithKline plc
 received on 15
 September 2008 from Legal & General Group plc a notification of interests in GlaxoSmithKline plc Ordinary 
shares of 25 pence each, dated 15
 September 2008. This notice is given in accordance with DTR 5.8.12.



TR-1:
    
NOTIFICATION OF MAJOR INTERESTS IN SHARES



1.
 Identity of the i
ssuer or
 the underlying issuer of existing shares to which voting rights are attached:
GlaxoSmithKline Plc
2. Reason for notification (yes/no)
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached 

An event changing the breakdown of voting rights

Other (please specify):______________

3. Full name of person
(s)
 subject to the notification obligation:
Legal & General Group Plc (Group)

Legal & General Investment Management Limited (LGIM)
4. Full name of shareholder
(s)
 
(if different from 3.):
Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Group Plc (L&G)

5. Date 
of the transaction
 
(and date on which the threshold is crossed or reached if different):

12 
September 2008

6. Date on which issuer notified:

15 September 2008

7. Threshold(s) that 
is/are
 crossed or reached:

Above 5% (Group)

Above 5% (LGIM)



8. Notified details:



A:
 Voting rights attached to shares
Class/type of shares
 
 if possible using the ISIN CODE
Situation previous to the 
Triggering transaction 
Resulting situation after the triggering transaction
Number of Shares 
Number of Voting Rights 
Number of shares 
Number of voting rights
% of voting rights
Direct
Indirect
Direct
Indirect
ORD
GBP 0.25
Below 5%
261,627,964
243,825,427
17,802,537
4.66
0.34



B:
 Financial Instruments
Resulting situation after the triggering transaction
 
Type of financial instrument 
Expiration date
 
Exercise/
 
Conversion Period/ Date
 
Number of voting rights 
that may be acquired if the instrument is exercised/ converted. 
% of voting rights
   
   
   
   
   



Total (A+B)
Number of voting rights
% of voting rights
261,627,964
5.00




9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) (261,627,964 – 5.00% = Total Position)
 
 
Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (261,627,964 – 5.00% = Total Position)
 
 
Legal & General Investment Management Limited (Indirect) (LGIM) (261,627,964 – 5.00% = Total Position)
 
 
Legal & General Group Plc (Direct) (L&G) (243,825,427 – 4.66 % = LGAS, LGPL & PMC)
Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) (200,083,369 – 3.82 % = PMC)
 
Legal & General Insurance Holdings Limited (Direct) (LGIH)
Legal & General Assurance (Pensions Management) Limited (PMC) (200,083,369 – 3.82 % = PMC) 
 
Legal & General Assurance Society Limited (LGAS & LGPL)
 
Legal & General Pensions Limited (Direct) (LGPL)


 
 


Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A



13. Additional information:
Notification using 
the total voting rights
 figure of 
5,226,596,384

14. Contact name:
Helen Lewis
 (LGIM)
15. Contact telephone number:
020 3124 3851



 

 

 

 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: September 16, 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc